We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Near-Patient Molecular Test Outperforms Other Rapid Measures for Sepsis Diagnosis

By LabMedica International staff writers
Posted on 22 Mar 2023
Print article
Image: SeptiCyte RAPID offers a revolutionary way to diagnose sepsis (Photo courtesy of Immunexpress)
Image: SeptiCyte RAPID offers a revolutionary way to diagnose sepsis (Photo courtesy of Immunexpress)

Sepsis is a life-threatening condition that can lead to organ failure and death, causing high in-patient costs for hospitals. Detecting sepsis early is crucial, and a quick sepsis test can make a significant difference between life and death. Overuse of antibiotics can also result in new health issues and antibiotic resistance among at-risk patient populations. Thus, early detection can help health professionals determine the most effective treatment plan quickly, including potential ICU admission. However, conventional blood tests for sepsis based on microbiological culture are not reliable or speedy enough. Now, a PCR-based test for sepsis has demonstrated that it can more accurately determine if an ICU patient has sepsis as compared to other rapid diagnostic methods.

SeptiCyte RAPID from Immunexpress (Brisbane, Australia) is a sample-to-answer, cartridge-based, host response molecular test for sepsis that uses reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes isolated from whole blood. SeptiCyte RAPID is utilized alongside clinical assessments, vital signs and laboratory findings to help distinguish infection-positive (sepsis) from infection-negative systemic inflammation response syndromes in patients with organ dysfunction and high infection risk. SeptiCyte RAPID generates a score (SeptiScore) that falls within four discrete interpretation bands depending upon the increasing possibility of sepsis.

In a new study, SeptiCyte RAPID proved more accurate in determining sepsis in ICU patients than other rapid diagnostic methods, including quick Sequential Organ Failure Assessment (qSOFA). SeptiCyte RAPID in conjunction with qSOFA was statistically significant at distinguishing higher as well as lower mortality sepsis patients in the ICU cases from those without sepsis and could act as the first step in diagnostic pathways for sepsis. For the study, the researchers utilized retrospective and prospective data from clinical trials involving 419 critically ill patients with systemic inflammatory response syndrome who had been admitted to the ICU for suspicion of having sepsis. A panel of three clinicians performing expert diagnosis classified the patients as sepsis positive, sepsis negative or indeterminate, and calculated a full qSOFA score for 173 patients.

SeptiCyte RAPID distinguished between sepsis positive patients and sepsis negative patients regardless of qSOFA stratification (AUC 0.82 in qSOFA ≥2, AUC 0.81 in qSOFA < 2) and also outperformed several conventional rapid diagnosis methods such as SOFA, lactate, PCT, among other parameters. Additionally, SeptiCyte RAPID outperformed other sepsis markers in differentiating higher and lower mortality ICU cases from patients that did not have sepsis. SeptiCyte RAPID is intended for in-vitro diagnostic use and runs on the Biocartis Idylla Platform. SeptiCyte RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). As of November 2021, the test has been markers FDA cleared for use in hospitalized patients suspected of sepsis.

"This study demonstrates that SeptiCyte RAPID is not only a more accurate sepsis diagnostic tool compared to other conventional rapid diagnosis methods but can serve as a crucial first step in the diagnostic and treatment paradigm for patients suspected of sepsis using the Sepsis-3 framework. While conventional sepsis diagnosis is based on parameters such as qSOFA, PCT, lactate, white cell count, respiratory rate and temperature, SeptiCyte RAPID measures the mRNA expression of two genes that are specific to sepsis," commented Dr. Richard Brandon, Chief Scientific Officer of Immunexpress. "Emergency medicine outcomes rely on quick decision-making and action. SeptiCyte RAPID is uniquely positioned to provide clinicians in this field with actionable results in less than an hour and may be utilized early in the diagnostic pathway to determine the likelihood of sepsis. In conjunction with additional parameters of qSOFA and SOFA scores, SeptiCyte RAPID may aid clinicians in predicting the likelihood of septic shock or other unwanted health outcomes."

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.